Ito T, Asai F, Oshima T, Kobayashi S
Biological Research Laboratories, Sankyo Co., Ltd., Japan.
Thromb Res. 1990 Aug 15;59(4):735-47. doi: 10.1016/0049-3848(90)90055-h.
To clarify whether activated platelets play an important role in the occurrence and exacerbation of disseminated intravascular coagulation (DIC), we investigated the effects of 4 anti-platelet drugs, a PGI2 analog (CS-570), a thromboxane synthetase inhibitor (dazoxiben), a thromboxane receptor antagonist (BM-13177), and ticlopidine, in an experimental DIC model in rats. Experimental DIC was induced by a continuous infusion of lipopolysaccharide (LPS derived from E. coli, 055 B5, 25 mg/kg/hr) for 4 hrs. In the time-course determination of the coagulation parameters and prostanoids, an abrupt increase in TxB2 (a stable metabolite of TxA2) and 6-keto-PGF1 alpha (a stable metabolite of PGI2) was followed by a decrease in platelet count, a prolongation of blood coagulation time, and an increase in fibrinogen/fibrin degradation products (FDP). Four hours after the start of LPS infusion, the rats were considered to be in the state of DIC. The effects of the anti-platelet drugs were investigated 4 hrs after the start of LPS infusion. CS-570 and ticlopidine ameliorated DIC in a dose-dependent manner. CS-570 (10 micrograms/kg/min) improved DIC in the platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fbg), and FDP, without affecting TxB2 and 6-keto-PGF1 alpha formation. Ticlopidine (200 mg/kg, i.p.) prevented the exacerbation of DIC in such item parameters as platelet count, APTT, and FDP. Both dazoxiben and BM-13177 (30 mg/kg, i.p.) ameliorated DIC in following parameters as platelet count, APTT and FDP. Dazoxiben, but not BM-13177, significantly inhibited the increase in TxB2 concentration at 4 hr. These observations suggest that drugs which inhibit platelet activation by a TxA2-dependent route are effective in improving DIC induced by LPS, and that drugs which inhibit multiple platelet-activating routes improve DIC in more item parameters than drugs which inhibit only the TxA2-dependent activating route. Consequently, it is concluded that activated platelets might play an important role in the occurrence and exacerbation of DIC induced by LPS, and that one of the roles of TxA2 in DIC is to activate platelets.
为阐明活化血小板在弥散性血管内凝血(DIC)的发生和加重过程中是否起重要作用,我们在大鼠实验性DIC模型中研究了4种抗血小板药物的作用,即前列环素(PGI2)类似物(CS - 570)、血栓素合成酶抑制剂(达唑氧苯)、血栓素受体拮抗剂(BM - 13177)和噻氯匹定。通过持续输注脂多糖(源自大肠杆菌055 B5,25 mg/kg/hr)4小时诱导实验性DIC。在对凝血参数和前列腺素进行时间进程测定时,血栓素B2(TxA2的稳定代谢产物)和6 - 酮 - 前列腺素F1α(PGI2的稳定代谢产物)突然增加,随后血小板计数下降、凝血时间延长以及纤维蛋白原/纤维蛋白降解产物(FDP)增加。脂多糖输注开始4小时后,大鼠被认为处于DIC状态。在脂多糖输注开始4小时后研究抗血小板药物的作用。CS - 570和噻氯匹定以剂量依赖方式改善DIC。CS - 570(10微克/千克/分钟)在血小板计数、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fbg)和FDP方面改善了DIC,而不影响TxB2和6 - 酮 - 前列腺素F1α的形成。噻氯匹定(200毫克/千克,腹腔注射)在血小板计数、APTT和FDP等项目参数方面防止了DIC的加重。达唑氧苯和BM - 13177(30毫克/千克,腹腔注射)在血小板计数、APTT和FDP等参数方面改善了DIC。达唑氧苯而非BM - 13177在4小时时显著抑制了TxB2浓度的升高。这些观察结果表明,通过依赖TxA2的途径抑制血小板活化的药物在改善脂多糖诱导的DIC方面是有效的,并且抑制多种血小板活化途径的药物比仅抑制依赖TxA2的活化途径的药物在更多项目参数上改善DIC。因此,可以得出结论,活化血小板可能在脂多糖诱导的DIC的发生和加重中起重要作用,并且TxA2在DIC中的作用之一是激活血小板。